• STAAR Surgical reported past first-quarter 2026 results with net sales of US$93.52 million, a very large increase from US$42.59 million a year earlier, and moved from a net loss to net income of US$5.21 million.
• The quarter underscored how resurgent demand in China for EVO+ lenses, combined with expanding U.S. indications and tighter cost control, has transformed the company’s profitability profile.
• We’ll now examine how this sharp earnings rebound, powered by EVO+ lens demand in China, reshapes STAAR Surgical’s investment narrative.

Find 51 companies with promising cash flow potential yet trading below their fair value.

STAAR Surgical Investment Narrative Recap

To own STAAR Surgical, you need to believe that lens based refractive surgery, especially EVO and EVO+, can support a durable, profitable niche in vision correction. The most important short term catalyst is sustained EVO+ demand in China and stable distributor inventory there, while the biggest risk is renewed volatility from that same market. The Q1 2026 earnings rebound strongly supports the China recovery story, but does not remove exposure to macro, regulatory and competitive pressures.

The most relevant recent announcement here is the FDA’s approval expanding the EVO and EVO+ ICL age indication in the U.S. from 21–45 to 21–60. Paired with the Q1 surge in China, this broadens STAAR’s addressable market in two key geographies at once, tying directly into the core catalyst of product adoption across regions. It also partially offsets concentration risk in China, even as China remains the primary swing factor for earnings.

Yet behind the strong quarter, investors should be aware of how dependent STAAR still is on China exposure and policy shifts...

STAAR Surgical's narrative projects $363.2 million revenue and $24.6 million earnings by 2029. This requires 14.9% yearly revenue growth and a $105 million earnings increase from -$80.4 million today.

Uncover how STAAR Surgical's forecasts yield a $21.11 fair value, a 34% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$390 million and earnings about US$52 million within a few years, so this surprise profit and China driven rebound might either reinforce that bullish view or prompt a rethink of how concentrated STAAR still is in ICLs and Chinese regulatory risk.

Explore 2 other fair value estimates on STAAR Surgical - why the stock might be worth as much as $27.50!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your STAAR Surgical research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free STAAR Surgical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate STAAR Surgical's overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.